Drug resistance in pancreatic cancer: Impact of altered energy metabolism

Cristoforo Grasso, Gerrit Jansen, Elisa Giovannetti

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

Pancreatic cancer is a highly deadly disease: almost all patients develop metastases and conventional treatments have little impact on survival. Therapeutically, this tumor is poorly responsive, largely due to drug resistance. Accumulating evidence suggest that this chemoresistance is intimately linked to specific metabolic aberrations of pancreatic cancer cells, notably an increased use of glucose and the amino acid glutamine fueling anabolic processes. Altered metabolism contributes also to modulation of apoptosis, angiogenesis and drug targets, conferring a resistant phenotype. As a modality to overcome chemoresistance, a variety of experimental compounds inhibiting key metabolic pathways emerged as a promising approach to potentiate the standard treatments for pancreatic cancer in preclinical studies. These results warrant confirmation in clinical trials. Thus, this review summarizes the impact of metabolic aberrations from the perspective of drug resistance and discusses possible novel applications of metabolic inhibition for the development of more effective drugs against pancreatic cancer.

Original languageEnglish
Pages (from-to)139-152
Number of pages14
JournalCritical Reviews in Oncology/Hematology
Volume114
DOIs
Publication statusPublished - 1 Jun 2017

Cite this

@article{98800eb1c4744c0aa465ac3552d62245,
title = "Drug resistance in pancreatic cancer: Impact of altered energy metabolism",
abstract = "Pancreatic cancer is a highly deadly disease: almost all patients develop metastases and conventional treatments have little impact on survival. Therapeutically, this tumor is poorly responsive, largely due to drug resistance. Accumulating evidence suggest that this chemoresistance is intimately linked to specific metabolic aberrations of pancreatic cancer cells, notably an increased use of glucose and the amino acid glutamine fueling anabolic processes. Altered metabolism contributes also to modulation of apoptosis, angiogenesis and drug targets, conferring a resistant phenotype. As a modality to overcome chemoresistance, a variety of experimental compounds inhibiting key metabolic pathways emerged as a promising approach to potentiate the standard treatments for pancreatic cancer in preclinical studies. These results warrant confirmation in clinical trials. Thus, this review summarizes the impact of metabolic aberrations from the perspective of drug resistance and discusses possible novel applications of metabolic inhibition for the development of more effective drugs against pancreatic cancer.",
keywords = "Cancer metabolism, Drug resistance, New metabolically-targeted agents, Pancreatic cancer",
author = "Cristoforo Grasso and Gerrit Jansen and Elisa Giovannetti",
year = "2017",
month = "6",
day = "1",
doi = "10.1016/j.critrevonc.2017.03.026",
language = "English",
volume = "114",
pages = "139--152",
journal = "Critical Reviews in Oncology / Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",

}

Drug resistance in pancreatic cancer : Impact of altered energy metabolism. / Grasso, Cristoforo; Jansen, Gerrit; Giovannetti, Elisa.

In: Critical Reviews in Oncology/Hematology, Vol. 114, 01.06.2017, p. 139-152.

Research output: Contribution to journalReview articleAcademicpeer-review

TY - JOUR

T1 - Drug resistance in pancreatic cancer

T2 - Impact of altered energy metabolism

AU - Grasso, Cristoforo

AU - Jansen, Gerrit

AU - Giovannetti, Elisa

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Pancreatic cancer is a highly deadly disease: almost all patients develop metastases and conventional treatments have little impact on survival. Therapeutically, this tumor is poorly responsive, largely due to drug resistance. Accumulating evidence suggest that this chemoresistance is intimately linked to specific metabolic aberrations of pancreatic cancer cells, notably an increased use of glucose and the amino acid glutamine fueling anabolic processes. Altered metabolism contributes also to modulation of apoptosis, angiogenesis and drug targets, conferring a resistant phenotype. As a modality to overcome chemoresistance, a variety of experimental compounds inhibiting key metabolic pathways emerged as a promising approach to potentiate the standard treatments for pancreatic cancer in preclinical studies. These results warrant confirmation in clinical trials. Thus, this review summarizes the impact of metabolic aberrations from the perspective of drug resistance and discusses possible novel applications of metabolic inhibition for the development of more effective drugs against pancreatic cancer.

AB - Pancreatic cancer is a highly deadly disease: almost all patients develop metastases and conventional treatments have little impact on survival. Therapeutically, this tumor is poorly responsive, largely due to drug resistance. Accumulating evidence suggest that this chemoresistance is intimately linked to specific metabolic aberrations of pancreatic cancer cells, notably an increased use of glucose and the amino acid glutamine fueling anabolic processes. Altered metabolism contributes also to modulation of apoptosis, angiogenesis and drug targets, conferring a resistant phenotype. As a modality to overcome chemoresistance, a variety of experimental compounds inhibiting key metabolic pathways emerged as a promising approach to potentiate the standard treatments for pancreatic cancer in preclinical studies. These results warrant confirmation in clinical trials. Thus, this review summarizes the impact of metabolic aberrations from the perspective of drug resistance and discusses possible novel applications of metabolic inhibition for the development of more effective drugs against pancreatic cancer.

KW - Cancer metabolism

KW - Drug resistance

KW - New metabolically-targeted agents

KW - Pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=85018726704&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2017.03.026

DO - 10.1016/j.critrevonc.2017.03.026

M3 - Review article

VL - 114

SP - 139

EP - 152

JO - Critical Reviews in Oncology / Hematology

JF - Critical Reviews in Oncology / Hematology

SN - 1040-8428

ER -